<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[《中国临床新医学》杂志编辑部 -->呼吸疾病专栏]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Noticeable problems in diagnosis and treatment of invasive pulmonary aspergillosis]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190101&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Invasive pulmonary aspergillosis(IPA) represents a major complication in recipients of hematopoietic stem cell transplantation and solid-organ transplantation.The incidence of IPA in transplant recipients and in patients who have underlying lung diseases has increased over the past 20 years, and these infections continue to be associated with high morbidity and mortality. This article reviews some problems in terms of IPA diagnosis standard, classification of pulmonary aspergillosis, GM test and G test diagnostic value and clinical management of IPA.]]></description>
<pubDate>2019/1/31 16:31:41</pubDate>
<category><![CDATA[呼吸疾病专栏]]></category>
<author><![CDATA[ZHOU Xin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Xin</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190101&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[High-flow nasal oxygen]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190102&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　 High-flow nasal oxygen（HFNO） is a new type of oxygen therapy and has been applying in clinic widely. Recent studies finds that HFNO has many advantages over traditional oxygen therapy, and has similar effects with non-invasive ventilation in some patients with respiratory failure, which offers a new idea and choice for respiratory support in the patients with respiratory failure. However, the specific clinical indications of HFNO are still unclear, therefore, the rational use and standardized management of HFNO should be emphasized at present, and the application scopes still need to be further explored clinically. In this paper, the research progress of HFNO is reviewed.]]></description>
<pubDate>2019/1/31 16:31:41</pubDate>
<category><![CDATA[呼吸疾病专栏]]></category>
<author><![CDATA[LI Zheng-dong, ZHAN Qing-yuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Zheng-dong, ZHAN Qing-yuan</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190102&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Interpretation and thinking of the guideline for the diagnosis and treatment and prevention of pulmonary thromboembolism(the 2018 new edition)——Guide clinical practice with the evidence-based medicine guideline]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190103&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Pulmonary thromboembolism(PTE) is characterized by high incidence, high mortality and high disability rates. It is a major medical problem that seriously threatens human health. In recent years, related researches in the field of PTE have developed rapidly, and the existing guidelines are unable to fully meet the clinical needs of Chinese clinicians, based on which the guideline for the diagnosis and treatment and prevention of pulmonary thromboembolism is developed by Pulmonary Embolism and Pulmonary Vascular Diseases Group of Chinese Thoracic Society and Pulmonary Embolism and Pulmonary Vascular Disease Working Committee of Chinese Association of Chest Physicians to better guide the clinical practice of Chinese physicians. In this paper, we provide a detailed interpretation of the guideline for the diagnosis and treatment and prevention of pulmonary thromboembolism(the 2018 new edition).]]></description>
<pubDate>2019/1/31 16:31:41</pubDate>
<category><![CDATA[呼吸疾病专栏]]></category>
<author><![CDATA[ZHANG Yun-xia, ZHAI Zhen-guo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yun-xia, ZHAI Zhen-guo</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190103&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New insight in HRCT diagnosis of idiopathic pulmonary fibrosis]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190104&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Idiopathic pulmonary fibrosis(IPF) is a chronic progressive fibrosing interstitial pneumonia. It is a distinct clinical entity associated with the histologic and high-resolution CT(HRCT) appearance of usual interstitial pneumonia(UIP). The Fleischner Society provides an updated approach to the HRCT diagnosis of IPF. The possible UIP pattern, according to the 2011 ATS/ERS/JRS/ALAT guidelines, has been upgraded to a probable UIP pattern, which will contribute to providing clinicans with a more simple and straightforward clinical diagnosis of IPF.]]></description>
<pubDate>2019/1/31 16:31:41</pubDate>
<category><![CDATA[呼吸疾病专栏]]></category>
<author><![CDATA[LIU Yin, CAI Hou-rong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yin, CAI Hou-rong</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190104&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical research progress of eosinophils in chronic obstructive pulmonary disease]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190105&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　The role of eosinophils in patients with chronic obstructive pulmonary disease(COPD) has attracted much attention in recent years. Researchers have found that eosinophils are elevated in blood, airway and lung tissues in both stable and acute exacerbated COPD patients. Recent studies have showed that eosinophils are associated with the risk of acute exacerbation, mortality and lung function decline, and that eosinophils can predict the therapeutic response to glucocorticoids in patients with COPD.  This review focuses on the research progress of eosinophils as a biomarker in COPD.]]></description>
<pubDate>2019/1/31 16:31:41</pubDate>
<category><![CDATA[呼吸疾病专栏]]></category>
<author><![CDATA[HUANG Ke, YANG Ting]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Ke, YANG Ting</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190105&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Home non-invasive ventilation in stable chronic obstructive pulmonary disease]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190106&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Chronic obstructive pulmonary disease(COPD) is a common chronic respiratory disease. Dyspnea, which is the most characteristic symptom of COPD patients, decreases the patients′ quality of life. Hospitalization for acute-on-chronic respiratory failure of COPD usually makes the patients′ pulmonary function and quality of life worse. Long term home non-invasive ventilation(NIV) has become one of the rehabilitations for hypercapnic COPD patients. Bilevel positive airway pressure(BiPAP) mode is the best choice of NIV. High inspiratory pressure and appropriate NIV time daily improve the pulmonary function and parameters of blood gas analysis, lower the times of rehospitalization and better the quality of life for hypercapnic COPD patients. The treatment of home non-invasive ventilation in stable chronic obstructive pulmonary disease is reviewed in this paper.]]></description>
<pubDate>2019/1/31 16:31:41</pubDate>
<category><![CDATA[呼吸疾病专栏]]></category>
<author><![CDATA[QIN Zhi-qiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIN Zhi-qiang</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20190106&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>